Head and Neck Cancer Clinical Trial
— PRETOXISVerified date | April 2017 |
Source | University Hospital, Ghent |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Radiotherapy is an integral component of the current multimodality treatment approach in
locally advanced head and neck cancer (HNC). There is growing evidence that more aggressive
treatment regimens improve tumour control and survival. However, intensified treatment is at
the expense of increased toxicity, in particular severe acute mucositis. In addition and of
increasing importance, late and irreversible treatment-related side effects, including
xerostomia and swallowing dysfunction, occur in a considerable proportion of patients and
negatively affect quality of life.
High-risk human papilloma virus (HPV), specifically HPV type-16, is implicated as the
causative factor in a proportion of HNC, especially those of the oropharynx. HPV-related
cancers respond well to chemoradiotherapy compared to HNC related to tobacco and alcohol.
Furthermore, the incidence of HPV-related oropharyngeal cancer is rising in Western
countries. Given the significant toxicity associated with concurrent chemoradiotherapy,
subsets of patients could be managed differently.
The first objective of the project is to develop predictive models for radiation-induced
dysphagia and xerostomia in HNC patients. Clinical characteristics, treatment parameters,
dose-volume effects on healthy tissues and whole-genome genetic data will be considered. The
second objective of the project is to study the prognostic value of HPV status together with
a panel of tumour biomarkers in oropharyngeal cancer patients. The overall aim of the
project is to stratify patients according to the risks (side-effects) and benefits
(survival) of cancer treatment using the developed risk models. Clustering patients into
different risk categories may aid treatment decision making reducing therapy toxicity
without compromising survival.
Status | Completed |
Enrollment | 45 |
Est. completion date | April 2017 |
Est. primary completion date | April 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed squamous cell carcinoma of oral cavity, oropharynx, hypopharynx and larynx. Histologically confirmed cervical lymph node metastases of unknown primary cancer (CUP). For prognosis part of the study: only histologically confirmed squamous cell carcinoma of the oropharynx - Stages : Tany N1-3, T3-4 N0, T1-2 N0, if prophylactic neck irradiation is performed - Multidisciplinary decision of curative radiotherapy or radiochemotherapy - Karnofsky performance status = 70% - Age = 18 years old - Gender : male - female - Informed consent obtained, signed and dated before start of radiotherapy Exclusion Criteria: - Treatment combined with brachytherapy - Treatment combined with cetuximab or other targeted agents - Prior irradiation to the head and neck region - History of prior malignancies, except for cured non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease at least 5 years - Distant metastases - Pregnant or lactating women - Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study - Patients unlikely to comply with the protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study |
Country | Name | City | State |
---|---|---|---|
Belgium | Department of Radiotherapy, University Hospital Ghent | Ghent | |
Belgium | Department of Radiotherapy, University Hospital Leuven | Leuven |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Ghent | Centre Oscar Lambret, Maastro Clinic, The Netherlands, Universitaire Ziekenhuizen Leuven, University Ghent |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in dysphagia | Dysphagia during radiotherapy and at 6/12/18/24 months after the end of radiotherapy using the CTCAE (Common Terminology Criteria for Adverse Events) v4.0 scale. | during radiotherapy and at 6/12/18/24 months after the end of radiotherapy | |
Primary | change in xerostomia | xerostomia during radiotherapy and at 6/12/18/24 months after the end of radiotherapy using the CTCAE (Common Terminology Criteria for Adverse Events) v4.0 scale | during radiotherapy and at 6/12/18/24 months after the end of radiotherapy | |
Primary | change in overall survival | up to three years after study start | ||
Primary | change in disease specific survival | up to three years after study start | ||
Primary | change in progression-free survival | up to three years after study start | ||
Primary | appearance of distant metastasis | up to three years after study start | ||
Secondary | Change in weight loss | during radiotherapy and at 6/12/18/24 months after the end of radiotherapy | ||
Secondary | change of Quality of life | using the EORTC (European Organisation for Research and Treatment of Cancer ) quality of life questionnaire C30 and the hand and neck cancer specific quality of life questionnaire HN35 | pre-radiotherapy, at the last day of radiotherapy and post-radiotherapy (12/24 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |